|0.45|| +0.01 / +2.27%|
Delcath Systems, Inc. is a pharmaceutical and medical device company, which is focused on oncology and liver cancer therapy. Its proprietary drug and device combination product, Delcath Hepatic Delivery System is designed to administer high dose chemotherapy and other therapeutic agents to the liver, while controlling the systemic exposure of those agents. The company also initiated plans to investigate the Melblez kit for primary liver cancer; and focuses on the treatment of primary and metastatic liver cancers. Its proprietary product also delivers and filters melphalan hydrochloride under the trade name Delcath Hepatic CHEMOSAT Delivery System. Delcath Systems was founded on August 5, 1988 and is headquartered in New York, NY.
|Jennifer K. Simpson||President, Chief Executive Officer & Director|
|Barbra C. Keck||CFO, Secretary, CAO, VP & Controller|
|J. Chris Houchins||Senior Vice President-Clinical & Medical Affairs|
|Jason A. Rifkin||Vice President-Commercial Programs|
|John Purpura||EVP-Regulatory Affairs & Quality Assurance|